Aurinia Pharmaceuticals reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, while cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026.
AUPH · Aurinia Pharmaceuticals Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 31%
- Last earnings
- Feb 26, 2026
- Latest filing
- 10-Q · Oct 30
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Aurinia reported total revenue of $83.7 million for the three months ended September 30, 2026, up 14% from the prior-year period, and raised its 2026 total revenue guidance to $325 million to $330 million. Net income was $31.7 million for the quarter, flat year over year.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net product sales | $79.42M | FY2026 Q3 | +12.4% |
|
|
|||
| Planned enrollment | 150 | 2026 | — |
| repurchase of common shares | 5M | nine months ended September 30, 2026 | — |
| sites | 50 | 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUPH
this stock
Aurinia Pharmaceuticals Inc.
|
$1.97B | -7.8% | +20.4% | 6.4 | 5.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 30, 2026
- This year
- 16
Aurinia Pharmaceuticals reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, while cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUPH | -6.6% | -12.8% | -4.5% | -11.7% | -7.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.0% | -3.6% | +4.7% | -3.0% | -9.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.